- Home
- GH vs LVS Comparison
GH vs LVS Comparison
Compare GH & LVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | LVS |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 23.4B |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | GH | LVS |
|---|---|---|
| Price | $150.81 | $40.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 21 |
| Target Price | ★ $202.24 | $49.57 |
| AVG Volume (30 Days) | 1.7M | ★ 6.5M |
| Earning Date | 11-05-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 2.93% |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ 1.86 |
| Revenue | $982,021,000.00 | ★ $13,017,000,000.00 |
| Revenue This Year | $38.41 | $3.41 |
| Revenue Next Year | $35.18 | $3.99 |
| P/E Ratio | ★ N/A | $21.90 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $74.55 | $35.03 |
| 52 Week High | $191.05 | $70.45 |
Technical Indicators
Market Signals| Indicator | GH | LVS |
|---|---|---|
| Relative Strength Index (RSI) | 34.54 | 66.92 |
| Support Level | $140.86 | $35.16 |
| Resistance Level | $177.55 | $54.81 |
| Average True Range (ATR) | 9.94 | 1.06 |
| MACD | -2.28 | 0.68 |
| Stochastic Oscillator | 20.79 | 90.15 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About LVS Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, Sands generates all its EBITDA from Asia, with its casino operations generating the majority of sales.